Spruce Biosciences, Inc. (SPRB)

Market Cap	3.08M
Revenue (ttm)	2.91M
Net Income (ttm)	-55.45M
Shares Out	42.23M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,883
Average Volume	284,208
Open	0.0720
Previous Close	0.0710
Day's Range	0.0636 - 0.0730
52-Week Range	0.0570 - 0.6080
Beta	2.40
RSI	46.32
Earnings Date	Aug 8, 2025

About Spruce Biosciences

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 21
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPRB

Financial Performance

In 2024, Spruce Biosciences's revenue was $4.91 million, a decrease of -51.32% compared to the previous year's $10.09 million. Losses were -$53.04 million, 10.7% more than in 2023.